Related by context. All words. (Click for frequent words.) 66 Intervention Effectiveness 66 CAMMS# 66 Multicenter 66 NSABP B 66 Cholesterol Levels SPARCL 65 CLARITY TIMI 65 Randomized Double Blind 65 TAXUS ATLAS 65 Randomized Controlled Trial 64 Unstable Angina 64 Randomized Clinical Trial 64 Carotid Revascularization Endarterectomy vs. 64 Randomized Evaluation 64 Myocardial Infarction Study 64 Randomized Controlled Trials 64 Chemotherapeutic Agents 64 Randomized Double blind 64 Carotid Stenting 64 Clinical Antipsychotic Trials 63 Acute Ischemic Stroke 63 ExTRACT TIMI 63 Phase III placebo controlled 63 RE LY ® 63 Randomized Controlled 63 CARE HF 63 multicenter randomized controlled 63 Prospective Multicenter 63 randomized controlled multicenter 63 Intervention Trial 63 Adjuvant Chemotherapy 63 Randomized Phase III 63 Aggressive Drug Evaluation 63 Study Evaluating 63 Pooled Analysis 63 NEVO RES 63 Immunomedics Announces 63 CHAMPION PCI 63 Randomized Trials 63 Clinical Outcome 63 EURIDIS 62 Phase Ib II 62 Refractory Angina 62 CAPRIE 62 Initiated Phase 62 Patients Undergoing 62 Prospective Randomized 62 placebo controlled clinical 62 Combination REOLYSIN R 62 multicentre randomized controlled 62 ORACLE MS 62 Aggressive Reduction 62 multicenter multinational 62 Controlled Trial 62 ENDEAVOR III 62 blinded randomized placebo controlled 62 Phase Ib clinical 62 including eniluracil ADH 62 ENDEAVOR II 62 Phase III AFFIRM 62 Multicenter Phase 62 Improves Outcomes 62 Confirms Efficacy 62 Spectrum Pharmaceuticals Announces 62 Targeted Therapy 62 Completes Patient Enrollment 62 Oral Fingolimod 62 Patients Receiving 62 Left Ventricular Dysfunction 61 Randomized Phase 61 Decompensated Heart Failure 61 PORxin TM platforms 61 Prospective Randomized Trial 61 Randomised 61 Phase IIb III 61 BR.# 61 registrational Phase 61 Pivotal Trial 61 Intervention Effectiveness CATIE 61 Cardiotoxicity 61 Spine Patient Outcomes 61 Double Blind Placebo 61 multicenter Phase II 61 multicenter placebo controlled 61 Teriflunomide 61 multicenter randomized placebo controlled 61 Phase III Pivotal 61 Acute Coronary Syndromes 61 Risk Stratification 61 ADMIRE HF 61 Val HeFT 61 Shows Promise Against 61 AVOREN 61 Improves Survival 61 Clostridium difficile Infection 61 See CLINICAL PHARMACOLOGY 61 Randomized Phase II 61 Multicenter Automatic Defibrillator Implantation 61 ASSERT 61 Recurrent Breast Cancer 61 placebo controlled multicenter 61 Oral Calcitonin 61 multicenter Phase III 61 CALERIE 61 ENDEAVOR IV 61 RECORD1 61 number NCT# ClinicalTrials.gov 61 PARTNER Trial 61 HCV SPRINT 61 ONTARGET 61 Randomized Clinical Trials 61 Venous Thromboembolism 61 Completes Enrollment 61 MGd 61 RE MODEL 61 Randomized controlled 61 BRIM2 61 Novel Oral 61 Edge STudy 61 Pivotal Phase III 61 Stent Implantation 61 Lung Injury 61 REALITY Trial 60 Clinical Evaluation 60 Severe Sepsis 60 CYT# potent vascular disrupting 60 Pivotal Phase 60 CATIE AD 60 Prolongs Survival 60 Hemodialysis Patients 60 Meets Primary Endpoint 60 Platelet Inhibition 60 Appears Safe 60 candidates Augment ™ 60 EXPLORE Xa 60 Multicenter Randomized 60 MADIT II 60 Injectable Bone Graft 60 testing huN# DM1 60 Relapsed Multiple Myeloma 60 Coronary Angiography 60 Randomized Double Blind Placebo 60 Valsartan 60 Hospital Acquired Pneumonia 60 double blinded randomized 60 BCIRG 60 Long Lesion 60 placebo controlled Phase III 60 II Clinical Trial 60 AIR CF1 60 Initiates Enrollment 60 Recurrent Glioblastoma 60 PMX # heptagonist 60 fosbretabulin 60 Acute Myocardial Infarction 60 Phase 2b Clinical Trial 60 GEM OS2 60 multicentre randomized double 60 Newly Diagnosed Multiple Myeloma 60 Mg Usa 60 Relapsing Multiple Sclerosis 60 Xelox 60 Digital Mammographic Imaging 60 Fixed Dose 60 Teva Provides Update 60 phase IIb clinical 60 HOPE TOO 60 FOLFOX6 chemotherapy regimen 60 multicentre randomized 60 Phase IIIb 60 Phase III Clinical Trial 60 Initiates Phase III 60 Cardiovascular Outcomes 60 Tumor Response 60 prospective randomized multicenter 60 Proves Effective 60 Angiographic 60 Systematic Review 60 Shows Efficacy 60 Adjunctive Therapy 60 Clinical Efficacy 60 relapsed MM 60 Phase III randomized 60 SPIRIT FIRST 60 RE LY 60 Demonstrates Positive 60 Poster Presentations 60 Patients Treated With 60 Demonstrates Significant 60 Phase IIb Trial 60 CONQUER OB 59 prospective observational 59 PROTEGE 59 Clinical Outcomes Utilizing Revascularization 59 Cardiovascular Risk Reduction 59 Demonstrates Sustained 59 NPS Pharmaceuticals Announces 59 Myocardial Ischemia 59 Renal Function 59 Romidepsin 59 Pharmacokinetic Study 59 Thrombolysis 59 phase Ib clinical 59 dosing cohorts 59 ENDEAVOR IV clinical 59 Localized Prostate Cancer 59 Subgroup Analysis 59 Pivotal Study 59 nonrandomized 59 Venous Thrombosis 59 Advanced Melanoma 59 Glucosamine Chondroitin Arthritis 59 Heart Failure Patients 59 Percutaneous Coronary Intervention 59 Antihypertensive 59 phase IIIb 59 Diabetic Foot Ulcer 59 NCCTG N# 59 Combination Treatment 59 Coronary Revascularization 59 Subtypes 59 Drug Shows Promise 59 Bare Metal Stents 59 DIRECT Trial 59 Demonstrates Efficacy 59 Parathyroid Hormone 59 Demonstrate Significant 59 National Emphysema Treatment 59 TMC# C# 59 Clinical Outcomes 59 PEGINTRON TM 59 Remission Maintenance 59 Long Term Outcomes 59 Lung Cancers 59 cisplatin gemcitabine 59 recurrent malignant glioma 59 Sustained Efficacy 59 placebo controlled Phase 59 Clinical Trial Evaluating 59 REVIVE Diabetes 59 prospective multicentre 59 Randomized Placebo Controlled 59 Pivotal Trials 59 Phase #b/#a clinical 59 Cardiovascular Events 59 Initiates Phase II 59 Left Ventricular 59 Antigen Specific 59 Phase III Psoriasis 59 Restenosis 59 Diabetic Neuropathy 59 Long Term Efficacy 59 lenalidomide Revlimid R 59 Meta Analysis 59 Controlled Study 59 Metastatic Colorectal Cancer 59 Preclinical Data 59 Prostate Cancer Prevention 59 Elderly Patients 59 Initiates Clinical Trial 59 multicenter Phase 59 Deforolimus 59 Vertebral Fractures 59 Adjuvant Breast Cancer 59 vapreotide acetate 59 Trial Evaluating 59 Randomized Study 59 CALGB 59 Refractory Hodgkin Lymphoma 59 Initiate Phase 59 Unfractionated Heparin 59 familial amyloidotic polyneuropathy FAP 59 Randomized Placebo controlled 58 mg administered orally 58 Dialysis Outcomes 58 ECASS 58 Second Pivotal Phase 58 Placebo Controlled 58 Depressive Symptoms 58 Patient Outcomes 58 relapsing remitting MS RRMS 58 Acute Decompensated Heart Failure 58 Placebo controlled 58 Phase Ib IIa 58 Tyrosine Kinase Inhibitor 58 prospective randomized controlled 58 unfractionated heparin UFH 58 Bare Metal Stent 58 Primary endpoints 58 Previously Treated 58 Reduces Mortality 58 evaluating mipomersen 58 Liver Metastases 58 IMPACT DCM 58 Drug Eluting 58 Patients Enrolled 58 CLARITY study 58 Prevent Stroke 58 Antiviral Activity 58 Ovarian Cancer Screening 58 subanalysis 58 CHARM Added 58 TRANSDUR ™ 58 Phase III multicenter 58 Intervention Trial GAIT 58 landmark ATHENA 58 BARI 2D 58 oral rivaroxaban 58 angiotensin analog 58 GetGoal Phase III 58 Postmenopausal Women 58 Heterozygous Familial Hypercholesterolemia 58 Cardiovascular Risk Factors 58 lexidronam injection 58 Carotid Endarterectomy 58 evaluating Xcytrin 58 BRIM3 58 CALGB # [002] 58 PROTECT AF 58 AIR CF2 58 Pharmacokinetics PK 58 Coronary Artery Calcium 58 HCV Protease Inhibitor 58 Pediatric Patients 58 Screening Trial DMIST 58 evaluating tivozanib 58 Sirolimus Eluting Stent 58 NCT# ClinicalTrials.gov 58 Ischemic Stroke 58 ENESTnd 58 Aflibercept 58 LEVAQUIN ® 58 evaluating Actimmune 58 multicenter randomized 58 Catheter Ablation 58 bone marrow reticulin deposition 58 Multicentre 58 Brentuximab Vedotin SGN 58 ADVANCE PD 58 STRIDE PD 58 DASISION 58 Randomized 58 multicenter prospective 58 Patients Treated 58 Renal Cancer 58 Therapy Improves 58 RAVEL 58 Elotuzumab 58 Pegylated Liposomal Doxorubicin 58 Cardiac Resynchronization 58 Ozarelix 58 Renal Impairment 58 Fondaparinux 58 papillary renal cell carcinoma 58 Radiation Therapy Oncology 58 Truvada tablets 58 epoetin alpha 58 Matrix Phase 2b 58 Clinical Trial Results 58 phase III ACCLAIM 58 Observational Study 58 ENGAGE AF TIMI 58 Investigational Compound 58 trial evaluating PRX# 58 confirmatory clinical 58 THAT ARE DIFFICULT TO 58 Anti CD# Antibody 58 Pafuramidine 58 Uterine Cancer 58 Raloxifene STAR 58 Intravitreal 58 Complicated Skin 58 Confirmatory Phase 58 AVERROES 58 CURRENT OASIS 7 58 Desvenlafaxine Succinate 58 Adverse Event 58 SurModics Bravo 58 melphalan prednisone 58 Successfully Completes Phase 58 Cerebril TM 58 Secondary Hyperparathyroidism 58 multicenter randomized double 58 Antiplatelet Therapy 58 randomized multicenter 58 Adjuvant Treatment 58 Investigational Agent 58 VADT 58 multicenter randomized clinical 58 Vidaza ® 58 Coronary Artery Bypass Graft 58 ROCKET AF 58 Prognostic Factors 58 Phase III Trial 58 Inflammatory Arthritis 58 EVEREST II 58 Presents Positive 58 Perifosine KRX 58 Initiate Phase III 58 Hematological Cancers 58 CIMZIA TM certolizumab pegol 58 TRANSFORMS 57 HCV RESPOND 2 57 Adjuvant Therapy 57 Dual Antiplatelet Therapy 57 Vertebral Fracture 57 Microplasmin 57 Advanced Pancreatic Cancer 57 PREVENT IV 57 Preclinical Study 57 Single Dose 57 Multicenter Study 57 Well Tolerated 57 Therapeutic Efficacy 57 Potent Antiviral Activity 57 STENT 57 Preclinical Efficacy 57 Hormone Refractory Prostate Cancer 57 Evaluation WISE 57 Metastatic Melanoma 57 Treating Chronic 57 plus Copegus R 57 Dose Escalation 57 Meta analyzes 57 Vaccine Protects Against 57 ICON7 57 treatment naive genotype 57 randomized multicenter trial 57 sarcoma melanoma 57 Regimens 57 Patency 57 J Am Coll 57 Previously Untreated 57 Lipid Lowering 57 Phase 2b kidney transplant 57 #:#-#,# CrossRef Medline [002] 57 Neoadjuvant 57 PERSEUS 57 WHIMS 57 Surgical Treatment 57 Prosecution Rests Case 57 paclitaxel cisplatin 57 #-# Full Text 57 Study ARIC 57 Pivotal Clinical Trial 57 HGS ETR1 mapatumumab 57 TRANSDUR ® 57 prospective multicenter 57 COPERNICUS 57 ORENCIA ® 57 multicentre prospective 57 Phase III Clinical Trials 57 First Patient Enrolled 57 TRITON TIMI 57 meta regression 57 peginterferon alfa 2a Pegasys 57 Metastatic Prostate Cancer 57 rALLy clinical trial 57 Genes Predict 57 unique alkylating agent 57 receptor tyrosine kinase inhibitor 57 Study Shows Benefits 57 Immunotherapeutic 57 dose escalation clinical 57 galiximab 57 Renal Artery 57 Diabetic Macular Edema 57 Diagnostic Tests 57 Left Ventricular Hypertrophy 57 acyclovir Lauriad R 57 Clinical Trial Data 57 Optical Coherence Tomography 57 Orally Active 57 HORIZONS AMI 57 Multicenter Randomized Double 57 RNAi Therapeutic 57 Hypertensive adverse reactions 57 Reduced Incidence 57 Phase #/#a 57 SWOG 57 Commences Phase 57 Naive Patients 57 Prostate AdenoCarcinoma Treatment 57 Adenoma Prevention 57 Stent Restenosis 57 Nicotine Vaccine 57 Placebo Controlled Trial 57 Drug Combo 57 TIMI Study Group 57 Anti Tumor Activity 57 Polyp Prevention Trial 57 Postmenopausal 57 GOUT 57 Colorectal Cancer Patients 57 Metastatic Renal Cell Carcinoma 57 MADIT 57 Anthrax Toxin 57 Chronic Heart Failure 57 Node Positive 57 MKC# MT 57 5 Fluorouracil 57 Nebulized 57 Phase 2b Study 57 Surgical Procedures 57 Aneurysm Repair 57 Bone Metastases 57 Phase 2a Clinical Trial 57 REMINDER ORLive Presents 57 Demonstrates Potent 57 AVN# Phase 57 Hepatitis C Antiviral 57 Presents Preclinical Data 57 Phase III Trials 57 Early Relapsing Multiple 57 Shows Promising 57 myocardial infarction ventricular fibrillation 57 Vaccine Adjuvants 57 Progenitor Cells 57 evaluating carfilzomib 57 antidepressants fluoxetine 57 randomized blinded 57 Immunomodulatory 57 Statin Therapy 57 Rheumatoid Arthritis Patients 57 Collaborators Present 57 Dose Ranging 57 Enzastaurin 57 prospective observational studies 57 controlled multicenter Phase 57 bevacizumab Avastin ® 57 Infarct 57 Statistically Significant 57 prospective nonrandomized 57 Partial Onset Seizures 57 recombinant PSMA vaccine 57 Hepatotoxicity 57 FDA Approvals 57 TO AVOID PREGNANCY WHILE 57 Augment TM 57 Phase 1a clinical 57 Treatment Naive Patients 57 ANN INTERN MED 57 Investigational Drug 57 randomized controlled clinical 57 Treatment Resistant 57 Investigational Treatment 57 Alagebrium 57 basal bolus regimen 57 resectable pancreatic cancer 57 APEX PD 57 Initiate Phase II 57 Genes Linked 57 Paclitaxel Carboplatin 57 Liraglutide Effect 57 Phase 1b clinical trials 57 PCI ExTRACT TIMI 57 Asthma Intervention 57 Is Well Tolerated 57 Neoadjuvant Chemotherapy 57 Treatment Regimen 57 J Am Acad 57 recurrent glioblastoma multiforme 57 prospectively stratified 56 Treating Depression 56 MKC# MKC# PP 56 Hsp# Inhibitor 56 Study Demonstrates 56 Onyx Pharmaceuticals Announces 56 Eluting 56 DAPT 56 Treatment Naïve 56 risperidone Risperdal 56 MIST II 56 dirucotide MBP# 56 Unresectable 56 LUMINATE 56 Protease Inhibitors 56 CUSTOM III 56 MEND CABG 56 citalopram Celexa 56 Gastric Cancer 56 PFO migraine 56 RENAL 56 Insulin Glargine 56 microgram kg 56 Phase 2b Trial 56 Phase IIb Clinical Trial 56 docetaxel Taxotere ® 56 PEG IFN 56 Atypical Hemolytic Uremic Syndrome 56 Septic Shock 56 Fovea Pharmaceuticals subsidiary 56 ILLUSTRATE 56 Intracranial Aneurysms 56 Soft Tissue Sarcoma 56 Chemoradiation 56 pivotal bioequivalence 56 intradermal injections 56 Helps Predict 56 fallopian tube cancers 56 ATACAND 56 Breast Cancer Recurrence 56 stage IIIb IV 56 Ovitrelle R Serostim 56 Paclitaxel Eluting 56 ELADUR ™ 56 ALSYMPCA 56 Efficacy Results 56 Eculizumab 56 Radiofrequency Ablation 56 Vildagliptin 56 HER2 Positive 56 sodium thiosulfate STS 56 NATRECOR ® 56 Sleep Disturbances 56 Biomarker Study 56 cancer indications bafetinib 56 somatostatin analog 56 Sipuleucel T 56 Folfox 56 Tigecycline 56 Treatment Reduces 56 evaluating Vectibix 56 assessing T DM1 56 Rotavirus Vaccine 56 infliximab monotherapy 56 Pegylated Interferon 56 Ranolazine 56 INSPIRE Trial Phase III 56 ST Segment Elevation 56 Myocardial Perfusion 56 Rosuvastatin 56 MEK Inhibitor 56 Myocardial Infarction 56 Advanced Prostate Cancer 56 Demonstrated Significant 56 Monotherapy 56 novel orally inhaled 56 novel VDA molecule 56 Lung Cancer Survival 56 phase IIa clinical 56 Hepatitis C Genotype 56 Slow Progression 56 randomized Phase IIb 56 Prostate Lung Colorectal 56 Antiarrhythmic 56 Achieves Primary Endpoint 56 Phase Ib clinical trials 56 Treatment Shows Promise 56 Diabetic Nephropathy 56 NAVISTAR R 56 MIVI III 56 Telik Announces 56 Cerebral Amyloid Angiopathy 56 Phase Ib Clinical Trial 56 Comorbidities 56 Endovascular Valve Edge 56 EmbraceAC 56 Dose Ranging Study 56 CaPSURE 56 Carotid 56 Advaxis Phase 56 Sirolimus Eluting 56 Breast Cancers 56 Acute Stroke 56 oral Janus kinase 56 Small Molecule 56 randomized controlled trials RCTs 56 SORT OUT III 56 Additionally Nexavar 56 Investigational Oral 56 RIO Diabetes 56 cluster randomized controlled 56 HER2 Positive Breast Cancer 56 R# #mg BID 56 Lipid Lowering Treatment 56 HMG CoA reductase inhibitors 56 receiving INTRON 56 erlotinib Tarceva ® 56 VICTOR E3 56 aripiprazole Abilify 56 multicenter phase 56 Phase III ThermoDox 56 sorafenib Nexavar 56 MAGE A3 ASCI 56 relapsing multiple sclerosis 56 PRN FDA Approves 56 Estrogen Therapy 56 designated HVTN 56 Predict Risk 56 Glycemic Control 56 Am J Geriatr 56 First Patient Dosed 56 Bayer HealthCare Onyx Pharmaceuticals 56 TKB# 56 Valvular Heart Disease 56 oral dual endothelin 56 Improve Outcomes 56 Vaccine Adjuvant 56 Pivotal Phase II 56 Placebo Controlled Study 56 Preterm Labor 56 Hormone Receptor Positive 56 Telik logo TELINTRA 56 STEALTH C 56 prospective randomized placebo 56 VESTASYNC 56 HYVET 56 Test Detects 56 Phase IIa Clinical Trial 56 HCV NS5B polymerase 56 visceral metastases 56 TAFA# 56 evaluating T DM1 56 Current Controlled Trials 56 Replacement Therapy 56 Blind Placebo Controlled 56 Protease Inhibitor 56 Castration Resistant Prostate Cancer 56 Granted Orphan Drug 56 Genes Identified 56 dose regimens 56 Less Invasive 56 Antitumor Activity 56 Colorectal Cancers 56 Daptomycin 56 Study Evaluates 56 ORLive Presents 56 recurrent metastatic ovarian cancer 56 Systemic Sclerosis 56 placebo controlled dose escalation 56 candidate CRLX# 56 multicentre 56 Radical Prostatectomy 56 double blinded placebo 56 EnteroMedics proprietary neuroblocking technology 56 EOquin TM phase 56 ascending dose 56 Pharmacyclics Announces 56 evaluating REVLIMID 56 Lowers Risk 56 Autologous Stem Cell Transplantation 56 LHRH receptor positive 56 Launches Generic Version 56 Randomized Placebo Controlled Trial 56 placebo controlled studies 56 evaluating satraplatin plus 56 ZYBRESTAT fosbretabulin 56 Glufosfamide 56 sorafenib tablets 56 PRoFESS 56 #:#-#,# [002] 56 Files IND 56 Neuroendocrine Tumors 56 RELOVAIR ™ 55 Aromatase Inhibitors 55 IN PATIENTS WITH 55 blinded placebo controlled 55 Traficet EN 55 XIENCE V Stent System 55 Sapacitabine 55 demonstrated antitumor activity 55 paroxetine Paxil 55 ongoing Phase 1b 55 BOLDER II 55 oncolytic virus therapies 55 ToGA 55 Antiretroviral Therapy 55 Prophylactic Treatment 55 anastrazole 55 Sorafenib HCC Assessment 55 randomized multicentre 55 ziprasidone Geodon 55 Sangamo BioSciences Announces 55 Outpatient Setting 55 Circulating Tumor Cells 55 Hypertensive Patients 55 Myocardial Perfusion Imaging 55 COSTAR II 55 AIR2 Trial 55 Bipolar Depression 55 Blood Pressure Lowering 55 Tarceva TM 55 Adenoma 55 Anticoagulation 55 placebo controlled randomized 55 PET FROM 55 Improve Survival 55 Solid Tumors 55 de novo kidney transplant 55 Prove Effective 55 Stent Thrombosis 55 randomized discontinuation 55 treatment naïve genotype 55 lintuzumab SGN 55 Bone Mineral Density 55 Metabolic Efficiency 55 bile duct tumor 55 Phase IIA 55 Peripheral Arterial 55 randomized multicenter Phase III 55 Contrast Enhanced 55 Enrolling Patients 55 Genes Involved 55 COU AA 55 Stem Cell Transplants 55 Antitumor 55 Epilepsy Drug 55 Tolvaptan 55 randomized Phase III 55 SUTENT ® 55 REG2 55 Arch Neurol 55 ADVANCE ILLUMINATE 55 Systolic Hypertension 55 Juvenile Idiopathic Arthritis 55 Relieve Depression 55 Epoetin Alfa 55 Renal Cell Carcinoma 55 Randomized Comparison 55 riociguat 55 TORISEL TM 55 Multiple Myeloma Patients 55 retrospective cohort 55 doxorubicin cyclophosphamide 55 Intravenous immunoglobulin 55 Universal Flu Vaccine 55 GENASIS clinical 55 prospective multicenter randomized 55 LUX Lung 55 Liver Failure 55 RNAi Therapeutics 55 Albuferon TM 55 HDL Selective Delipidation 55 multicenter clinical 55 Knee Osteoarthritis 55 Dry Powder Inhalers 55 EchoCRT 55 ritonavir boosted 55 Treatment Outcome 55 Tumor Progression 55 investigational protease inhibitor 55 opioid naive 55 Xcytrin R 55 comparing XIENCE V 55 Orthostatic Hypotension 55 ID NCT# 55 irinotecan cisplatin 55 Critically Ill Patients 55 cardiac myosin activator omecamtiv 55 By JENNIFER LEARN 55 ASTEROID 55 HF ACTION 55 Cloretazine ® 55 Phase 1b clinical 55 Hepatocellular Carcinoma 55 Skin Lesions 55 Treatment Naive 55 colesevelam HCl 55 Kidney Transplant Patients 55 Crofelemer budesonide foam 55 Anticancer Activity 55 Relapsing Remitting Multiple Sclerosis 55 EINSTEIN DVT 55 EGFR HER2 55 Phase IIb randomized 55 Neulasta R 55 Medidur TM FA 55 NCT# 55 Plaque Psoriasis 55 NICE SUGAR 55 PEGINTRON REBETOL combination 55 VIVUS Announces 55 trials RCTs 55 Malignant Glioma 55 BARACLUDE R 55 Overactive Bladder 55 ORAL Sync 55 APTIVUS r 55 Amirhossein Sairafi 55 Abciximab 55 acute peripheral arterial 55 Pre RELAX AHF 55 Degarelix 55 Intra Arterial 55 Drug Eluting Stents 55 Endovascular Repair 55 paclitaxel Taxol R 55 Data Extraction 55 Hospitalized Patients 55 Virologic 55 Acute Heart Failure 55 JAK Inhibitor 55 multicenter 55 Epratuzumab 55 Preclinical Models 55 Acute Exacerbations 55 Chronic Hepatitis C 55 plus Copegus 55 Dose Response 55 Gene Linked 55 DEFER 55 Rigel R# 55 Present Preclinical Data 55 TDF FTC 55 TROPIC 55 Includes KCI proprietary 55 Bipolar Mania 55 Low Incidence 55 Randomized Trial 55 hypertrichosis occurred 55 pharmacokinetic PK study 55 randomized #:#:# 55 neoadjuvant 55 AAG geldanamycin analog 55 ZACTIMA 55 Stable Angina 55 Drug Prevents 55 Cancer Incidence Mortality 55 BiTE R 55 Artery Disease 55 metastatic HRPC 55 Central Retinal Vein 55 multicenter randomized Phase III 55 SABCS 55 Crit Rev 55 ER CHOP 55 postmenopausal osteoporotic women 55 Molecular Basis 55 Renal Anemia 55 undergoing elective percutaneous 55 NO# [002] 55 Lupus Drug 55 Osteoporosis Drugs 55 everolimus eluting stents 55 Azacitidine 55 catheter occlusion 55 GENASIS 55 Respiratory Distress 55 Myeloma Patients 55 Schizophrenia Treatment 55 Data Suggest 55 alfa 2a 55 interferon gamma 1b 55 mg q#h 55 CHARISMA trial 55 Ischaemic 55 prokinetic agent 55 immunomodulatory agents 55 Sandostatin R 55 Fracture Risk 55 MCSP respectively 55 Prospective Randomized Double 55 candidates Azedra TM 55 Functional Outcomes 55 Phase 1b trial 55 Gynecologic Oncology Group 55 Fungal Infections 55 nucleoside naive 55 pegylated liposomal doxorubicin 55 Diamyd Medical Diamyd 55 phase Ib 55 Fludarabine 55 CTA# Injection 55 sertraline Zoloft 55 #:#-#,# CrossRef Medline [001] 55 retinal vein occlusion induced 55 Inhaled Nitric Oxide 55 BENCHMRK 55 Viral Suppression 55 Omacetaxine 55 Metabolic Disease 55 Glatiramer Acetate 55 AIM HIGH 55 Adverse Effects 55 Oral Laquinimod 55 label multicenter 55 Intervention Trial Evaluating 55 worsening thrombocytopenia 55 Anti Tumor 55 orally inhaled migraine 55 induced macular edema 55 controlled multicenter 55 Shown Effective 55 tribulations Groenveld 55 complement inhibitor eculizumab 55 multicenter clinical trials 55 underwent CABG 55 FASLODEX 55 Endovascular Treatment 55 AML MDS 55 Percutaneous Tibial Nerve Stimulation 55 phase IIa 55 Osteoarthritis Patients 55 Prognostic Value 55 docetaxel chemotherapy 55 TEC #OL 55 Delcath Phase III 55 longitudinal observational study 55 Submits NDA